RxDoctor Payments Data

Jaber Khan, MD

Family Medicine · Asheboro, NCNPI 1205857182

Payments from drug & device makers

$11,427in general payments, 2019–2025

Across 684 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$954
  • Pfizer$656
  • GSK$629
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$11,36699%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk104$1,623
AstraZeneca62$1,321
AbbVie(2 entities)89$1,097
Lilly USA, LLC59$954
Pfizer46$656
GSK48$629
Preventric Diagnostics, Inc.1$605
Amgen34$504
Boehringer Ingelheim20$397
Merck18$281
Bayer17$243
Otsuka America Pharmaceutical, Inc.4$171
Esperion Therapeutics, Inc.9$163
Astellas Pharma US Inc12$160
Amarin Pharma, Inc.11$157
Exact Sciences7$133
Sanofi-aventis U.S. LLC8$132
Johnson & Johnson10$131
Takeda Pharmaceuticals U.S.A., Inc.8$110
Biohaven Pharmaceuticals, Inc.4$97
Cranial Technologies, Inc6$92
Genentech USA, Inc.5$79
Teva Pharmaceuticals USA, Inc.5$78
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$76
Sumitomo Pharma America, Inc.5$73
Aytu Biopharma, Inc.4$71
Eisai Inc.4$66
Daiichi Sankyo Inc.4$66
Sanofi Pasteur Inc.3$66
Novartis5$64
Kowa Pharmaceuticals America, Inc.5$61
Abbott3$57
Corcept Therapeutics3$52
Dexcom, Inc.3$51
Avion Pharmaceuticals3$49
Philips North America LLC1$48
Supernus Pharmaceuticals, Inc.3$48
Biohaven Pharmaceutical Holding Company Ltd.3$47
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$47
Ironwood Pharmaceuticals, Inc3$45
Mylan Specialty L.p.2$43
Xeris Pharmaceuticals, Inc.3$41
Ironshore Pharmaceuticals Inc.2$38
Phathom Pharmaceuticals, Inc.2$37
Medtronic2$35
Vanda Pharmaceuticals Inc.2$35
Axsome Therapeutics, Inc.2$32
Baxter Healthcare1$30
Corium, LLC2$30
Novavax Inc1$26
Paratek Pharmaceuticals, Inc.1$24
Valeritas, Inc.1$20
Seqirus USA Inc1$19
Adlon Therapeutics L.p.1$17
Collegium Pharmaceutical, Inc.1$16
Sunovion Pharmaceuticals Inc.1$16
Idorsia Pharmaceuticals US Inc1$16
Neurocrine Biosciences, Inc.1$16
ARS Pharmaceuticals Operations, Inc.1$15
Upsher-smith Laboratories LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,427 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$53,882
Medicare patients
127
Services billed
1,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$94,992
EliquisApixaban79$67,369
JardianceEmpagliflozin61$61,706
TrulicityDulaglutide29$33,581
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$33,288
MounjaroTirzepatide24$31,065
XareltoRivaroxaban25$27,108
FarxigaDapagliflozin Propanediol31$23,975
Synjardy XrEmpagliflozin/Metformin Hcl15$20,102
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$14,578
VascepaIcosapent Ethyl24$11,979
MyrbetriqMirabegron15$11,806
LinzessLinaclotide19$10,120
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$7,873
OxycontinOxycodone Hcl12$6,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat$397$96,385101 claims
Novo NordiskOzempic$1,623$94,99280 claims
PfizerEliquis, Paxlovid$656$70,16899 claims
Lilly USA, LLCTrulicity, Mounjaro$954$64,64653 claims
GSKTrelegy Ellipta$629$33,28850 claims
Johnson & JohnsonXarelto$131$27,10825 claims
AstraZenecaFarxiga$1,321$23,97531 claims
AbbVieLinzess, Synthroid$1,097$13,51656 claims
Astellas Pharma US IncMyrbetriq$160$11,80615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Asheboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →